Identification of the Microbiota Dependent Response to Rifaximin in Irritable Bowel Syndrome Patients

Trial Profile

Identification of the Microbiota Dependent Response to Rifaximin in Irritable Bowel Syndrome Patients

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2015

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Irritable bowel syndrome
  • Focus Pharmacodynamics
  • Most Recent Events

    • 04 Apr 2015 Status changed from recruiting to discontinued, according to European Clinical Trials Database record.
    • 08 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top